latest news releases from the newsroom
Enigma Software Group, Inc.
Enigma Software Group, Inc. Announces Negative Cash Flow for Year Ended December 31, 2005 and Liquidity Crisis
STAMFORD, Conn., April 11, 2006 (PRIMEZONE) -- Enigma Software Group, Inc. (OTCBB:ENGM), ("Enigma" and/or the "Company"), which yesterday filed its annual report to the Securities and Exchange Commission for the year ended December 31, 2005 on Form 10-KSB, announced that its Cash Flow from Operations for 2005 was negative and that it has continued to experience negative cash flow during the first quarter of 2006, which has given rise to a liquidity crisis for the Company.
MEDirect Latino, Inc.
MEDirect Latino Inc. Exceeds One Million Dollars in March Revenues
PLANTATION, Fla., April 11, 2006 (PRIMEZONE) -- MEDirect Latino Inc. (Pink Sheets:MLTO) (www.medirectlatino.org), the first national provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community, today announced record results for March 2006 in gross billings and new patient shipments. MEDirect Latino reports gross billings of $1,002,391 during the month, a 10.52% increase over February's billings of $906,936. The Company's gross product profit margins remained unchanged at 78%. Total new patient shipments for March numbered 4,421, an increase of 20.39% over February's shipments of 3,672. The Company's 'patient hold journal' (approved and pending shipment for regulatory processing), closed the month with 5,203 additional customer orders, an increase of 17% over February's 4,447 patient hold journal. MEDirect Latino expects to monetize its approved and pending patient orders in April, which is typical to the Company's model.
VioQuest Pharmaceuticals Discusses Targeted Therapeutics For Cancer on News 12 New Jersey
BASKING RIDGE, N.J., April 11, 2006 (PRIMEZONE) -- Pamela Harris, M.D., Chief Medical Officer and Dick Welter, Ph.D., Vice President of Corporate Business Development of VioQuest Pharmaceuticals (OTCBB:VQPH), discussed the emerging paradigm of personalized medicine during a taped interview which was aired by "12 to Your Health," a popular health show produced by New Jersey's News 12. Drs. Welter and Harris described how the advances in molecular biology have made it possible for physicians to profile the cancer-promoting steps in each patient's tumor and for pharmaceutical companies to develop treatments that "target" these steps. This kind of approach allows patients to get the best therapy for their particular cancer while not being exposed unnecessarily to toxic medications with little potential of helping them. The entire field of targeted therapeutics has already revolutionized and is likely to dominate cancer treatment for the foreseeable future. As Drs. Harris and Welter explained, VioQuest Pharmaceuticals is on the cutting edge of developing these targeted therapeutics.
Occidental Petroleum Corp.
Occidental to Hold Earnings Conference Call
LOS ANGELES, April 11, 2006 (PRIMEZONE) -- Occidental Petroleum Corporation (NYSE:OXY) will hold a conference call on Tuesday, April 25, 2006, following the release of its first-quarter 2006 financial results. The conference call, which will begin at 11:30 a.m. EST, may be accessed by calling 1-888-873-8496. The conference call also can be heard live on the company's website, www.oxy.com.